Multiple myeloma collection

502 abstracts

Abstract Multiple myeloma in the African American population: A 2010-2020 NCDB analysis. Organization:Chitwan Medical Coll...,Congress:ASCO 2024,ASCO 2020, Search all connections
Abstract Bayesian modeling in the survival analysis of patients with multiple myeloma with emphasis on missing data analysis Congress:ESMO 2024, Search all connections
Abstract Impact of chronic kidney disease on disease outcomes in hospitalized multiple myeloma patients: A National inpatient sample study from 2016 to 2020 Congress:ESMO 2024, Search all connections
Abstract Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma Congress:ESMO 2024, Search all connections
Abstract BALLOON-KYPHOPLASTY FOR THE TREATMENT OF OSTEOLYTIC VERTEBRAL FRACTURES CAUSED BY MULTIPLE MYELOMA – 3 YEARS PROSPECTIVE FOLLOW-UP Organization:Centrum für Muskulos...,Congress:EULAR 2008, Search all connections
Abstract AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: REVIEW OF 63 CASES Organization:Rheumatology, Societ...,Hematology, Farhat H...,Congress:EULAR 2016, Search all connections
Abstract A new bone prognostic factor in multiple myeloma (mm): level serum cross-laps (ctx) at diagnosis Organization:Clinical Pharmacy La...,Hematology Depmartme...,Congress:EULAR 2001, Search all connections
Abstract Cost-effectiveness of once weekly carfilzomib 70 mg⁄m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. Congress:ASCO 2019, Search all connections
Abstract Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM). Congress:ASCO 2019, Search all connections
Abstract Adherence and cumulative bisphosphonate dose in relation to risk of skeletal-related events among older patients with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Comparable survival of African-Americans and Caucasian patients with multiple myeloma: A hospital-based study including 117,926 patients. Congress:ASCO 2019, Search all connections
Abstract Racial differences in intravenous bisphosphonate utilization among older patients with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Racial and insurance disparities in multiple myeloma management in a referral center. Congress:ASCO 2019, Search all connections
Abstract Demographic characteristics of smoldering multiple myeloma patients: A hospital-based study including 11,643 patients. Congress:ASCO 2019, Search all connections
Abstract Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Contemporary therapy efficacy for high-risk multiple myeloma: A systematic review. Congress:ASCO 2019, Search all connections
Abstract Inching towards precision medicine for multiple myeloma with causal network models. Congress:ASCO 2019, Search all connections
Abstract Role of investigational monoclonal antibodies in the treatment of multiple myeloma: A systematic review. Congress:ASCO 2019, Search all connections
Abstract Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Role of extra corporeal methods for light chain removal on renal recovery in multiple myeloma: A systematic review. Congress:ASCO 2019, Search all connections
Abstract The unforeseen business and medical consequences of EHR data collection for a real-world data multiple myeloma registry. Congress:ASCO 2019, Search all connections
Abstract Clinical significance of CXCR5-CXCL13 signaling in multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of four drug regimens in newly diagnosed multiple myeloma: Systematic review. Congress:ASCO 2019, Search all connections
Abstract Time to first treatment is an independent prognostic factor for multiple myeloma (MM). Congress:ASCO 2019, Search all connections
Abstract Appendicular skeleton MRI in multiple myeloma: Utility and clinical implications. Congress:ASCO 2019, Search all connections
Abstract 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract The impact of newly approved drugs on clinical and operational strategies for multiple myeloma clinical trials. Congress:ASCO 2019, Search all connections
Abstract Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy. Congress:ASCO 2019, Search all connections
Abstract Incidence of serious adverse events in bortezomib, lenalidomide and bortezomib plus lenalidomide maintenance for multiple myeloma: Interim analysis of MMRF-CoMMpass study. Congress:ASCO 2019, Search all connections
Abstract Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience. Congress:ASCO 2019, Search all connections
Abstract The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. Congress:ASCO 2019, Search all connections
Abstract Treatment sequencing patterns for relapsed refractory multiple myeloma (RRMM) in the era of new therapies in a single center institution. Congress:ASCO 2019, Search all connections
Abstract Association between immunoglobulin isotypes and cytogenetic risk groups in multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study. Congress:ASCO 2019, Search all connections
Abstract Treatment patterns in patients with multiple myeloma (MM): A retrospective study using Medicare data. Congress:ASCO 2019, Search all connections
Abstract Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). Congress:ASCO 2019, Search all connections
Abstract A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Congress:ASCO 2019, Search all connections
Abstract Self-reported health and survival in older patients diagnosed with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Impact of race/ethnicity in the clinical presentation and outcomes of patients with multiple myeloma in an underserved urban population. Congress:ASCO 2019, Search all connections
Abstract Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS). Congress:ASCO 2019, Search all connections
Abstract SGNBCMA-001: A phase 1 study of SEA‑BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). Congress:ASCO 2019, Search all connections
Abstract Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2019, Search all connections
Abstract Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6). Congress:ASCO 2019, Search all connections
Abstract ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status. Congress:ASCO 2019, Search all connections
Abstract A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM). Congress:ASCO 2019, Search all connections
Abstract Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Congress:ASCO 2019, Search all connections
Abstract Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory multiple myeloma (rrMM). Congress:ASCO 2019, Search all connections
Abstract Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. Congress:ASCO 2019, Search all connections
Abstract Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line. Congress:ASCO 2019, Search all connections
Abstract Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk. Congress:ASCO 2019, Search all connections
Abstract Continued improvement in survival in multiple myeloma (MM) including high-risk patients. Congress:ASCO 2019, Search all connections
Abstract Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients. Congress:ASCO 2019, Search all connections
Abstract Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03). Congress:ASCO 2019, Search all connections
Abstract Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. Congress:ASCO 2019, Search all connections
Abstract Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC). Congress:ASCO 2019, Search all connections
Abstract Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Congress:ASCO 2019, Search all connections
Abstract Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry. Congress:ASCO 2019, Search all connections
Abstract Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS). Congress:ASCO 2019, Search all connections
Abstract Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR. Congress:ASCO 2019, Search all connections
Abstract Minimal residual disease clinical monitoring and depth of response in multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment. Congress:ASCO 2019, Search all connections
Abstract Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Effect of iFISH defined 1q21 amplification/gain in multiple myeloma patients treated on total therapy protocols. Congress:ASCO 2019, Search all connections
Abstract Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM). Congress:ASCO 2019, Search all connections
Abstract Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. Congress:ASCO 2019, Search all connections
Abstract Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. Congress:ASCO 2019, Search all connections
Abstract Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). Congress:ASCO 2019, Search all connections
Abstract Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study. Congress:ASCO 2019, Search all connections
Abstract Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Insurance status and survival of multiple myeloma (MM) patients. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. Congress:ASCO 2019, Search all connections
Abstract A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2019, Search all connections
Abstract First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2019, Search all connections
Abstract Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. Congress:ASCO 2019, Search all connections
Abstract E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. Congress:ASCO 2019, Search all connections
Abstract Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. Congress:ASCO 2019, Search all connections
Abstract Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. Congress:ASCO 2019, Search all connections
Abstract The influence of clinical stage, race, and gender on factors which impact quality of life in multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Feasibility of digital life coaching during stem cell transplantation for multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract U.S. budget impact (BI) model for selinexor, bortezomib, and dexamethasone (XVd) for the treatment of patients with previously treated multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Evaluation of multiple myeloma clinical decision support tool value for assessing treatment selection variation when populated with community health system data. Congress:ASCO 2021, Search all connections
Abstract Changes in chronic disease medication adherence following oral anticancer agent initiation in patients with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Treatment response among patients with multiple myeloma initiating daratumumab across different lines of therapy: A real-world chart review study. Congress:ASCO 2021, Search all connections
Abstract Real-world treatment patterns and outcomes of triple-exposed multiple myeloma patients treated in community oncology practices in the United States. Congress:ASCO 2021, Search all connections
Abstract Patient-reported outcomes in clinical trials for multiple myeloma: Where we are. Congress:ASCO 2021, Search all connections
Abstract Health disparities experienced by Black Americans with multiple myeloma in the United States: A population-based study. Congress:ASCO 2021, Search all connections
Abstract Differences in disease characteristics and outcomes in older versus younger adults with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Recent updates on three drug combination regimen for relapsed refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Bispecific CART cells in the treatment of relapsed and refractory multiple myeloma: A review of literature. Congress:ASCO 2021, Search all connections
Abstract Clinical and financial implications of central venous catheters bloodstream infections in patients with multiple myeloma in the United States. Congress:ASCO 2021, Search all connections
Abstract Continuous genomic monitoring of multiple myeloma patients to identify patients of high risk for poor prognosis. Congress:ASCO 2021, Search all connections
Abstract Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Choosing optimal therapy for relapsed refractory multiple myeloma: A systematic review and network meta-analysis. Congress:ASCO 2021, Search all connections
Abstract Characterization of smoldering multiple myeloma: A population-based cohort study. Congress:ASCO 2021, Search all connections
Abstract Acute and chronic cancer-related distress among multiple myeloma patients during the COVID-19 pandemic. Congress:ASCO 2021, Search all connections
Abstract Patient-reported experience platform identifies discordance between guidelines and real-world practice: Maintenance therapy for high-risk multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract A pilot study of physical activity in newly diagnosed elderly patients with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Patient-reported efficacy and toxicity in CAR T-cell therapy for multiple myeloma via Internet-based platforms. Congress:ASCO 2021, Search all connections
Abstract Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM). Congress:ASCO 2021, Search all connections
Abstract Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs). Congress:ASCO 2021, Search all connections
Abstract Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. Congress:ASCO 2021, Search all connections
Abstract Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review. Congress:ASCO 2021, Search all connections
Abstract Single cell multiomic analysis and immune cell type profiling of multiple myeloma with t(4;14). Congress:ASCO 2021, Search all connections
Abstract Clinical presentation of multiple myeloma by race/ethnicity and Asian subgroup in an integrated healthcare system. Congress:ASCO 2021, Search all connections
Abstract Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials. Congress:ASCO 2021, Search all connections
Abstract Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM). Congress:ASCO 2021, Search all connections
Abstract Correlation of Agent Orange exposure, cytogenetics, and clinical outcomes in multiple myeloma and MGUS. Congress:ASCO 2021, Search all connections
Abstract Effect of acute kidney injury on hospital-based outcomes in patients with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Physical function, cognitive impairment, and quality-of-life among adults with multiple myeloma and associated plasma cell disorders. Congress:ASCO 2021, Search all connections
Abstract Outcomes of patients with multiple myeloma treated at a regional Australian center compared to a metropolitan Australian center. Congress:ASCO 2021, Search all connections
Abstract Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI). Congress:ASCO 2021, Search all connections
Abstract Retrospective study to assess the impact of hepatitis C virus infection on the prognosis and management of multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience. Congress:ASCO 2021, Search all connections
Abstract Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. Congress:ASCO 2021, Search all connections
Abstract Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study. Congress:ASCO 2021, Search all connections
Abstract A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. Congress:ASCO 2021, Search all connections
Abstract KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation. Congress:ASCO 2021, Search all connections
Abstract LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts). Congress:ASCO 2021, Search all connections
Abstract Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. Congress:ASCO 2021, Search all connections
Abstract Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis. Congress:ASCO 2021, Search all connections
Abstract Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2021, Search all connections
Abstract Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway. Congress:ASCO 2021, Search all connections
Abstract Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies. Congress:ASCO 2021, Search all connections
Abstract Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Congress:ASCO 2021, Search all connections
Abstract LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy. Congress:ASCO 2021, Search all connections
Abstract High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients. Congress:ASCO 2021, Search all connections
Abstract Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA. Congress:ASCO 2021, Search all connections
Abstract Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients. Congress:ASCO 2021, Search all connections
Abstract Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2. Congress:ASCO 2021, Search all connections
Abstract ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results. Congress:ASCO 2021, Search all connections
Abstract Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis. Congress:ASCO 2021, Search all connections
Abstract 5-Hydroxymethylcytosines in circulating cell-free DNA and overall survival in patients with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. Congress:ASCO 2021, Search all connections
Abstract Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Congress:ASCO 2021, Search all connections
Abstract Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study. Congress:ASCO 2021, Search all connections
Abstract Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD. Congress:ASCO 2021, Search all connections
Abstract Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf). Congress:ASCO 2021, Search all connections
Abstract Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel). Congress:ASCO 2021, Search all connections
Abstract Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. Congress:ASCO 2021, Search all connections
Abstract Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). Congress:ASCO 2021, Search all connections
Abstract Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial. Congress:ASCO 2021, Search all connections
Abstract Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial. Congress:ASCO 2021, Search all connections
Abstract Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. Congress:ASCO 2021, Search all connections
Abstract Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial. Congress:ASCO 2021, Search all connections
Abstract Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. Congress:ASCO 2021, Search all connections
Abstract MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. Congress:ASCO 2021, Search all connections
Abstract CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. Congress:ASCO 2021, Search all connections
Abstract Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system. Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. Congress:ASCO 2021, Search all connections
Abstract Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. Congress:ASCO 2021, Search all connections
Abstract Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Congress:ASCO 2021, Search all connections
Abstract The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302). Congress:ASCO 2021, Search all connections
Abstract Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). Congress:ASCO 2021, Search all connections
Abstract Real-world healthcare resource utilization and costs among patients with multiple myeloma in the United States. Congress:ASCO 2022, Search all connections
Abstract Optimizing rural healthcare: A retrospective review of initial diagnostic workup for multiple myeloma or monoclonal gammopathy. Congress:ASCO 2022, Search all connections
Abstract Gender disparities in multiple myeloma publications. Congress:ASCO 2022, Search all connections
Abstract T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis. Congress:ASCO 2022, Search all connections
Abstract Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy. Congress:ASCO 2022, Search all connections
Abstract Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Using electronic health records to derive a synthetic control arm for a historical trial on relapsed/refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract Implications of 18F-FDG PET/CT findings before autologous stem cell transplant in patients with multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract A systematic review on smoldering multiple myeloma: Whether treatment is beneficial. Congress:ASCO 2022, Search all connections
Abstract Smoldering multiple myeloma progression to multiple myeloma in a community-based population. Congress:ASCO 2022, Search all connections
Abstract Step-up titration dosing (TD) of carfilzomib (K) is associated with prolonged duration of therapy and improved treatment outcomes compared to standard dosing (SD) in patients with multiple myeloma (MM). Congress:ASCO 2022, Search all connections
Abstract Short- and long-term outcomes of multiple myeloma patients undergoing modern treatments proceeding to ASCT: A retrospective analysis. Congress:ASCO 2022, Search all connections
Abstract A retrospective study of the association of pre-autologous stem cell transplantation disease status with outcomes in patients with multiple myeloma: A single-center study. Congress:ASCO 2022, Search all connections
Abstract From triple-class exposed (TCE) to penta-exposed and triple-class refractory (PE-TCR): Real-world outcomes across a spectrum of advanced relapsed or refractory multiple myeloma (RRMM) patients (Pts) in the United States. Congress:ASCO 2022, Search all connections
Abstract Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in NOVEL agents' era. Congress:ASCO 2022, Search all connections
Abstract The association between minimal residual disease status and survival outcomes in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients: Systematic review. Congress:ASCO 2022, Search all connections
Abstract Incidence and risk factors for bacterial infection in newly diagnosed multiple myeloma patients undergoing treatment with bortezomib, lenalidomide, and dexamethasone (RVD). Congress:ASCO 2022, Search all connections
Abstract Geographic disparity between patients with multiple myeloma (non-Whites and Whites). Congress:ASCO 2022, Search all connections
Abstract Body mass index and overall survival in multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Retrospective analysis of responses to second-line treatments of multiple myeloma after disease progression in patients who underwent ASCT. Congress:ASCO 2022, Search all connections
Abstract Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet. Congress:ASCO 2022, Search all connections
Abstract Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Development of blood components samples collection as a source for new biomarkers search in multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Sequential EHR-based dynamic graph network for multiple myeloma detection and feature interaction investigation. Congress:ASCO 2022, Search all connections
Abstract Understanding barriers and facilitators to clinical trial participation among Black patients with multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort. Congress:ASCO 2022, Search all connections
Abstract Self-reported financial difficulties among patients with multiple myeloma and chronic lymphocytic leukemia: An Alliance for Clinical Trials in Oncology study. Congress:ASCO 2022, Search all connections
Abstract Survival among patients with multiple myeloma in the U.S. military health system compared to the Surveillance, Epidemiology, and End Results (SEER) program. Congress:ASCO 2022, Search all connections
Abstract Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study. Congress:ASCO 2022, Search all connections
Abstract MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14. Congress:ASCO 2022, Search all connections
Abstract MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Analysis of long-term outcomes in R-ISS stage 2 multiple myeloma with and without the presence of high-risk cytogenetics. Congress:ASCO 2022, Search all connections
Abstract COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). Congress:ASCO 2022, Search all connections
Abstract Evaluating serum-free light chain ratio as a biomarker for multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach. Congress:ASCO 2022, Search all connections
Abstract Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract The association of agent orange (AO) exposure with monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) progression: A population-based study. Congress:ASCO 2022, Search all connections
Abstract Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California. Congress:ASCO 2022, Search all connections
Abstract Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival. Congress:ASCO 2022, Search all connections
Abstract Retrospective review of outcomes of patients with multiple myeloma with COVID-19 infection (two-center study). Congress:ASCO 2022, Search all connections
Abstract Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy. Congress:ASCO 2022, Search all connections
Abstract Outcomes for transplant-eligible, newly diagnosed Black patients (Pts) with multiple myeloma (MM): The Levine Cancer Institute (LCI) experience. Congress:ASCO 2022, Search all connections
Abstract Early intervention for high-risk and low-risk of progression for patients with smoldering multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211). Congress:ASCO 2022, Search all connections
Abstract Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study. Congress:ASCO 2022, Search all connections
Abstract Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. Congress:ASCO 2022, Search all connections
Abstract A patient perspective on cure in multiple myeloma: A survey of over 1,500 patients. Congress:ASCO 2022, Search all connections
Abstract African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients. Congress:ASCO 2022, Search all connections
Abstract Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Congress:ASCO 2022, Search all connections
Abstract Demographic disparities in genomic data and clinical trials for multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results. Congress:ASCO 2022, Search all connections
Abstract Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Prevalence of ocular comorbidities in patients with multiple myeloma: An analysis of U.S. claims data. Congress:ASCO 2022, Search all connections
Abstract Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy. Congress:ASCO 2022, Search all connections
Abstract Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study. Congress:ASCO 2022, Search all connections
Abstract Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1. Congress:ASCO 2022, Search all connections
Abstract A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). Congress:ASCO 2022, Search all connections
Abstract Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study. Congress:ASCO 2022, Search all connections
Abstract Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. Congress:ASCO 2022, Search all connections
Abstract Association of socioeconomic status with adherence to oral agents in patients with multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. Congress:ASCO 2022, Search all connections
Abstract Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry. Congress:ASCO 2022, Search all connections
Abstract Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results. Congress:ASCO 2022, Search all connections
Abstract Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty. Congress:ASCO 2022, Search all connections
Abstract Development of B-cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. Congress:ASCO 2022, Search all connections
Abstract Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1. Congress:ASCO 2022, Search all connections
Abstract Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy. Congress:ASCO 2022, Search all connections
Abstract Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study. Congress:ASCO 2022, Search all connections
Abstract Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. Congress:ASCO 2022, Search all connections
Abstract Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. Congress:ASCO 2022, Search all connections
Abstract Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. Congress:ASCO 2022, Search all connections
Abstract Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A. Congress:ASCO 2022, Search all connections
Abstract Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN. Congress:ASCO 2022, Search all connections
Abstract Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM). Congress:ASCO 2022, Search all connections
Abstract Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). Congress:ASCO 2022, Search all connections
Abstract Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). Congress:ASCO 2022, Search all connections
Abstract Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Congress:ASCO 2022, Search all connections
Abstract Major risk factors associated with severe COVID-19 outcomes in patients with multiple myeloma: Report from the National COVID-19 Cohort Collaborative (N3C). Congress:ASCO 2022, Search all connections
Abstract Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. Congress:ASCO 2022, Search all connections
Abstract Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS). Congress:ASCO 2022, Search all connections
Abstract ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Congress:ASCO 2022, Search all connections
Abstract Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. Congress:ASCO 2022, Search all connections
Abstract Feasibility of cryocompression for bortezomib-induced peripheral neuropathy (BIPN) among patients with multiple myeloma (MM). Organization:Atrium Health Wake F...,Wake Forest Universi...,Drug:bortezomib,Target:Proteasome,Congress:ASCO 2023, Search all connections
Abstract Use of Myeloma Patient Outcome Scale (MyPOS) to gauge the effectiveness of palliative management in patients with multiple myeloma: Experience from a large tertiary academic center in India. Organization:Nuvance Health,Arlington, NY,All India Institute ...,Drug:Tramadol,oral morphine,Target:Tramadol,Mu opioid receptor, Search all connections
Abstract A pilot study to determine the effects of early palliative care integration on patients with newly diagnosed multiple myeloma. Organization:Cleveland Clinic Tau...,Taussig Cancer Insti...,Congress:ASCO 2023, Search all connections
Abstract Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis. Organization:Department of Intern...,Division of Hematolo...,Massachusetts Genera..., Search all connections
Abstract Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study. Organization:RTI Health Solutions,Pfizer Inc., London,...,Drug:proteasome inhibitor...,immunomodulatory dru...,anti-CD38 monoclonal..., Search all connections
Abstract Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study. Organization:Cerner Enviza,Pfizer Inc., London,...,Drug:pomalidomide-bortezo...,dexamethasone,carfilzomib-dexameth..., Search all connections
Abstract Experience of a stem cell transplant in multiple myeloma: The patient and care partner perspective. Organization:H. Lee Moffitt Cance...,Janssen Scientific A...,Janssen Pharmaceutic...,Congress:ASCO 2023, Search all connections
Abstract Functional status and therapy receipt among older adults with multiple myeloma. Organization:University of North ...,University of North ...,University of North ...,Drug:triplet therapy,stem cell transplant,Target:triplet therapy,Congress:ASCO 2023, Search all connections
Abstract Addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma. Organization:Penn State College o...,Penn State Milton S....,Drug:fluoroquinolones,doxycycline,ciprofloxacin,Target:Matrix metalloprotei..., Search all connections
Abstract Impact of primary language on health inequities in multiple myeloma. Organization:Department of Intern...,Chobanian and Avedis...,Section of Hematolog...,Drug:multiple myeloma,Congress:ASCO 2023, Search all connections
Abstract Clinical outcomes and national information of patients with multiple myeloma (MM) covered under the largest national health insurance in a low-middle-income country. Organization:Centro Integral de C...,nueva eps,Clinica De Occidente,Drug:proteasome inhibitor...,immunomodulators,Target:proteasome inhibitor...,Proteasome, Search all connections
Abstract Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES). Organization:Department of Cancer...,Roswell Park Compreh...,UM/Sylvester Compreh...,Drug:NCT04920084,NCT05640843,NCT05312255,Target:NCT05640843, Search all connections
Abstract Impact of time period of diagnosis, race, and military exposures on the survival of US military veterans with multiple myeloma and/or plasmacytoma. Organization:University of Califo...,Division of Hematolo...,Department of Medici...,Congress:ASCO 2023, Search all connections
Abstract Denosumab for smoldering multiple myeloma: Rates of osteoporosis and change in lowest T-score after 12 months of treatment. Clinical trial:UMMY18121,Organization:University of Roches...,Wilmot Cancer Instit...,Rochester, NY,Drug:denosumab,zoledronic acid,Target:RANKL,Congress:ASCO 2023, Search all connections
Abstract FISH abnormalities in Agent Orange–associated multiple myeloma. Organization:University Hospitals...,Case Comprehensive C...,Cleveland VA Medical...,Drug:Agent Orange,Target:TP53,Congress:ASCO 2023, Search all connections
Abstract Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience. Organization:H. Lee Moffitt Cance...,University of South ...,Drug:venetoclax,bortezomib,dexamethasone, Search all connections
Abstract Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB. Clinical trial:72023,Organization:University of Arkans...,Jordan University of...,University of Arkans...,Drug:lenalidomide,bortezomib, Search all connections
Abstract Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Organization:Hematology Unit, Ist...,Istituto Scientifico...,University Federico ..., Search all connections
Abstract Identifying associations between race and gender in the incidence and mortality of patients with multiple myeloma. Organization:Northeast Georgia Me...,University of Colora...,Congress:ASCO 2023, Search all connections
Abstract Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT). Organization:The University of Ka...,Levine Cancer Instit...,Mitchell Cancer Inst..., Search all connections
Abstract Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. Organization:Massachusetts Colleg...,Vanderbilt Universit...,Vanderbilt-Ingram Ca...,Drug:Teclistamab,Elranatamab,daratumumab,Product:talquetamab, Search all connections
Abstract In hospital outcomes and mortality predictors of multiple myeloma on stroke hospitalizations: A multivariable logistic regression study on the National Inpatient Sample Database. Organization:Louis A Weiss Memori...,Weiss Memorial Hospi...,Rawalpindi Medical U...,Drug:bortezomib,Target:26S proteasome,Congress:ASCO 2023, Search all connections
Abstract A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy. Clinical trial:Pro2020-0369,Organization:John Theurer Cancer ...,Hackensack Universit...,Georgetown Lombardi ...,Drug:Selinexor,carfilzomib-dexameth..., Search all connections
Abstract Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update. Organization:Myeloma Service, Dep...,Flaum Eye Institute,...,Washington Universit..., Search all connections
Abstract Health-related quality of life among patients with multiple myeloma treated with CAR-T therapy. Organization:Winship Cancer Insti...,Winship Cancer Cente...,Drug:CAR-T,Target:B-cell maturation an...,Congress:ASCO 2023, Search all connections
Abstract A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma. Clinical trial:Pro2021-0842,Organization:John Theurer Cancer ...,Hackensack Universit...,Georgetown Lombardi ...,Drug:iberdomide,carfilzomib-dexameth..., Search all connections
Abstract Non-vitamin k oral antagonists versus aspirin for primary thromboprophylaxis in patients with multiple myeloma on outpatient chemotherapy: A systematic review and meta-analysis. Organization:Federal University o...,Mount Sinai Mornings...,Icahn School of Medi...,Drug:NOACs, Search all connections
Abstract The efficacy of autologous hematopoietic cell transplantation in standard risk multiple myeloma refractory to multiple therapies. Organization:Department of Transl...,Lerner Research Inst...,Cleveland Clinic Tau...,Drug:AHCT,Congress:ASCO 2023, Search all connections
Abstract Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma. Organization:First Affiliated Hos...,Shanghai OrigiMed Co...,Congress:ASCO 2023, Search all connections
Abstract A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment. Clinical trial:C1071003,Organization:Pfizer Inc., London,...,Cytelligen, San Dieg...,Drug:Elranatamab,belantamab mafodotin,Selinexor,Target:B-cell maturation an..., Search all connections
Abstract Socioeconomic factors associated with a late-stage multiple myeloma diagnosis: An analysis of the National Cancer Database. Organization:Creighton University...,Creighton Hematology...,Congress:ASCO 2023, Search all connections
Abstract Determinants of overall survival (OS) of elderly patients with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017. Organization:Cleveland Clinic Flo...,Weston, FL,Congress:ASCO 2023, Search all connections
Abstract Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study. Clinical trial:EAE-2020/MM0107,Organization:Department of Clinic...,Department of Clinic...,Health Data Speciali...,Drug:belantamab mafodotin,Belamaf,lenalidomide, Search all connections
Abstract Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma. Organization:Mayo Clinic,Division of Hematolo...,Department of Intern...,Drug:daratumumab,IMiDs,lenalidomide, Search all connections
Abstract Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery Multiple Myeloma dataset. Organization:Walter Reed National...,David Grant USAF Med...,Drug:anti-myeloma therapy,Target:Multiple Myeloma,Congress:ASCO 2023, Search all connections
Abstract Patterns and risk factors of infection and its impact in outcomes of newly diagnosed multiple myeloma. Organization:Fundacion Santa Fe d...,NewYork-Presbyterian...,New York Oncology He...,Drug:bortezomib,Target:Proteasome,Congress:ASCO 2023, Search all connections
Abstract External validation of venous thromboembolism risk prediction models in patients with multiple myeloma in a community setting: A retrospective cohort study. Organization:Saint Vincent Hospit...,University of Pittsb...,Saint Vincent Cancer...,Product:TMZ,Drug:dexamethasone,doxorubicin, Search all connections
Abstract Role of PETCT in multiple myeloma: A 3 year data analysis of tertiary care center. Organization:Sarvodaya Hospital, ...,Sarvodaya Hospital, ...,Drug:FDG,Congress:ASCO 2023, Search all connections
Abstract Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients. Organization:HealthTree Foundatio...,The University of Ut...,Drug:daratumumab,lenalidomide,bortezomib,Target:Cereblon,glucocorticoid recep..., Search all connections
Abstract Trends in presentation, treatment, and survival in young multiple myeloma patients age 50 and under from 2000-2021. Organization:University of Califo...,University of Califo...,Drug:t(4;14),del17p,t(14;16),Target:t(14;16),t(4;14),del17p, Search all connections
Abstract Racial bias in multiple myeloma clinical trials: Racial minorities continue to miss out on treatment advances. Organization:Mount Sinai Hospital,BP Koirala Institute...,Georgia Cancer Cente...,Congress:ASCO 2023, Search all connections
Abstract Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1. Clinical trial:C1071001,Organization:Holden Comprehensive...,Arnie Charbonneau Ca...,Moores Cancer Center..., Search all connections
Abstract Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3. Clinical trial:C1071003,Organization:UCLA Medical Center,...,Arnie Charbonneau Ca...,Baylor University Me..., Search all connections
Abstract A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients—A nationwide cross-sectional study. Organization:Emilio Aguinaldo Col...,Icahn School of Medi...,University of Medici..., Search all connections
Abstract Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor. Clinical trial:KCP-330-012,Organization:Michigan State Unive...,Karmanos Cancer Inst...,McLaren Greater Lans..., Search all connections
Abstract Longitudinal changes in echocardiographic variables and endothelial function to predict cardiovascular toxicities in patients with multiple myeloma receiving carfilzomib. Organization:University of Chicag...,University of Chicag...,Drug:carfilzomib-dexameth...,Target:Proteasome,Congress:ASCO 2023, Search all connections
Abstract Outcomes of patients with multiple myeloma refractory to different administration schedules of bortezomib. Organization:Mayo Clinic,Drug:lenalidomide,bortezomib,cyclophosphamide,Target:TNFα,Proteasome, Search all connections
Abstract Demographic and socioeconomic determinants to the access to hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM): A National Cancer Database (NCDB) analysis of years 2004-2017. Organization:Cleveland Clinic Flo...,Weston, FL,Drug:chemo-immunotherapie...,novel agents,Target:Multiple Myeloma,Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM). Clinical trial:KCP-330-017,Organization:Queen Elizabeth II H...,David Geffen School ...,Banner MD Anderson C..., Search all connections
Abstract Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy. Organization:Department of Intern...,UT Health Sciences C...,University of Texas ...,Drug:BCMA CAR T,Anti-BCMA CAR T, Search all connections
Abstract Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs). Clinical trial:BB2121-MM-001,Organization:Bristol Myers Squibb,Princeton Health,Lille University Hos...,Drug:Tocilizumab, Search all connections
Abstract Trends in hematopoietic stem cell transplantation for leukemia, lymphoma and multiple myeloma in the United States: 2016 to 2020. Organization:Howard University Ho...,Howard University Ca...,Drug:multiple myeloma,Hodgkin lymphoma,Non-Hodgkin lymphoma, Search all connections
Abstract Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM). Organization:Icahn School of Medi...,Current Health,Dorset County Hospit...,Drug:chimeric antigen rec...,Target:CD33,CD19, Search all connections
Abstract Geriatric-assessment-guided interventions for older adults with multiple myeloma: A feasibility study. Organization:University of North ...,Chapel Hill, NC,UNC Lineberger Compr...,Congress:ASCO 2023, Search all connections
Abstract Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells. Organization:H. Lee Moffitt Cance...,Senior Adult Oncolog...,Moffitt Cancer Cente...,Drug:idecabtagene vicleuc...,ciltacabtagene autol..., Search all connections
Abstract The role of private insurance characteristics in the out-of-pocket costs of patients with multiple myeloma. Organization:Cleveland Clinic Tau...,Cleveland, OH,Drug:bortezomib,lenalidomide,carfilzomib-dexameth...,Target:PSMB7,lenalidomide,PSMB1, Search all connections
Abstract An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM). Clinical trial:C1071024,Organization:University of Alabam...,Duke University Scho...,Bethanien Hospital,Drug:Elranatamab, Search all connections
Abstract Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort. Organization:Karmanos Cancer Inst...,Wayne State Universi...,Memorial Sloan Kette...,Congress:ASCO 2023, Search all connections
Abstract EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clinical trial:CC-220-MM-002,Organization:Winship Cancer Cente...,St. Vincent’s Hospit...,University of Melbou..., Search all connections
Abstract OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma. Clinical trial:ANV419-001,Organization:Anaveon,Institute of Medical...,Department of Intern..., Search all connections
Abstract A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. Clinical trial:CA057-008,Organization:Dana-Farber Cancer I...,Bristol Myers Squibb,Institute for Myelom...,Drug:mezigdomide, Search all connections
Abstract MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Clinical trial:CR109244,Organization:Centre Hospitalier U...,Clinica São Germano,...,Columbia University ...,Drug:Teclistamab, Search all connections
Abstract CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. Clinical trial:CO43476,Organization:Mayo Clinic,Sarah Cannon Transpl...,Genentech,Drug:Cevostamab,anti-BCMA antibodies,proteasome inhibitor..., Search all connections
Abstract MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. Clinical trial:C1071007,Organization:Salamanca University...,Department of Hemato...,Division of Hematolo...,Drug:Elranatamab,lenalidomide, Search all connections
Abstract A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial). Organization:Sarah Cannon Researc...,Department of Hemato...,Icahn School of Medi..., Search all connections
Abstract MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). Clinical trial:C1071006,Organization:Department of Hemato...,Drug:Elranatamab,daratumumab,Target:BCMA×CD3,CD3,CD38,Congress:ASCO 2023, Search all connections
Abstract Utilizing a two-step frailty assessment strategy in older adults with multiple myeloma (MM): A decision curve analysis. Organization:Department of Hemato...,University of Alabam...,Institute for Cancer...,Congress:ASCO 2023, Search all connections
Abstract T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention. Organization:Department of Cancer...,Roswell Park Compreh...,Congress:ASCO 2023, Search all connections
Abstract Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database. Organization:Weill Cornell Medici...,University College D...,Drug:ASCT,triplet induction,Zanubrutinib,Target:TP53,MYC,Congress:ASCO 2023, Search all connections
Abstract Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma. Organization:Division of Hematolo...,Division of Hematopa...,University of Manito...,Drug:TeloView,Target:telomeres,Congress:ASCO 2023, Search all connections
Abstract Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. Organization:University of Arkans...,Jordan University of...,University of Arkans...,Drug:thalidomide,bortezomib,lenalidomide, Search all connections
Abstract Lenalidomide-based monotherapy versus augmented therapy for maintenance in standard risk multiple myeloma patients with no complete response post autologous hematopoietic cell transplantation. Organization:Department of Transl...,Heart Vascular Thora...,Cleveland Clinic Tau...,Drug:lenalidomide,Target:Cereblon,Congress:ASCO 2023, Search all connections
Abstract A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency. Clinical trial:STUDY00000007,Organization:Emory University Sch...,UPMC Cancer Center -...,Winship Cancer Insti...,Drug:daratumumab,bortezomib,dexamethasone, Search all connections
Abstract Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Organization:Mayo Clinic,Division of Hematolo...,Department of Intern...,Drug:daratumumab,ASCT,Target:CD38,Congress:ASCO 2023, Search all connections
Abstract Retrospective analysis of the relationship between time to anti-resorptive therapy and incidence of skeletal related events in patients with multiple myeloma. Organization:Sidney Kimmel Cancer...,Thomas Jefferson Uni...,Sidney Kimmel Medica...,Drug:anti-resorptive agen...,Target:bone resorption, Search all connections
Abstract Determinants of overall survival of young adults with multiple myeloma: A National Cancer Database (NCDB) analysis of years 2004-2017. Organization:Cleveland Clinic Flo...,Drug:HSCT,Congress:ASCO 2023, Search all connections
Abstract Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies. Organization:Memorial Sloan Kette...,MSKCC,Myeloma Service,Drug:Teclistamab,anti-CD38 monoclonal...,BCMA targeted ADCs, Search all connections
Abstract Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study. Clinical trial:EAE-2020/MM0107,Organization:Department of Clinic...,Drug:belantamab mafodotin,lenalidomide,dexamethasone,Target:lenalidomide,Dexamethasone,BCMA×CD3, Search all connections
Abstract Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma. Organization:Xilis.Inc,Durham Veteran Affai...,NC Medical Research,Drug:bortezomib, Search all connections
Abstract Clinical characteristics, markers of adverse prognosis, and predictors of development of extramedullary multiple myeloma. Organization:Mayo Clinic,Mayo Clinic (Rochest...,Mayo Clinic Departme...,Congress:ASCO 2023, Search all connections
Abstract ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM). Clinical trial:2015-0148,Organization:Department of Lympho...,The University of Te...,Department of Myelom..., Search all connections
Abstract Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM). Clinical trial:842603, UPCC 45419,Organization:Abramson Cancer Cent...,Perelman School of M...,University of Pennsy...,Drug:Tasquinimo,ixazomib, Search all connections
Abstract Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1. Clinical trial:CR108404,Organization:Janssen Research & D...,Sarah Cannon Researc...,City of Hope Compreh...,Drug:talazoparib,Target:G protein–coupled re...,Congress:ASCO 2023, Search all connections
Abstract Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study. Clinical trial:C1071003,Organization:Sorbonne University ...,Hôpital Saint-Antoin...,INSERM UMRs938, Search all connections
Abstract Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel). Clinical trial:BB2121-MM-001,Organization:Bristol Myers Squibb,Mount Sinai Medical ...,Dana-Farber Cancer I...,Drug:Ide-cel,Target:B-cell maturation an...,Congress:ASCO 2023, Search all connections
Abstract Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Organization:State Key Laboratory...,National Clinical Re...,Institute of Hematol..., Search all connections
Abstract Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. Clinical trial:CR108206,Organization:Memorial Sloan Kette...,Centre Hospitalier L...,Hopital Bretonneau, Search all connections
Abstract Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). Clinical trial:CR108404,Organization:Myeloma Center, Univ...,Drug:talazoparib,Target:G protein–coupled re...,Congress:ASCO 2023, Search all connections
Abstract Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT). Clinical trial:BB2121-MM-003,Organization:MD Anderson Cancer C...,Bristol Myers Squibb,Evidera, Inc, Search all connections
Abstract Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM). Clinical trial:BB2121-MM-003,Organization:Bristol Myers Squibb,Princeton, NJ,Massachusetts Genera..., Search all connections
Abstract Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. Clinical trial:I 47217,Organization:Roswell Park Compreh...,IU Simon Comprehensi...,Vanderbilt-Ingram Ca...,Drug:abatacept,ixazomib,dexamethasone, Search all connections
Abstract Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring. Organization:CNIO-H120 Lung Cance...,Altum Sequencing,UC3M Computer Scienc...,Congress:ASCO 2023, Search all connections
Abstract Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study. Clinical trial:EFC15246,Organization:Sanofi,Translational Genomi...,City of Hope Cancer ...,Drug:Isa-Kd,KD6001,Target:1q21, Search all connections
Abstract CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1). Organization:Department of Hemato...,Department of Hemato...,Department of Hemato..., Search all connections
Abstract Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies. Organization:Mayo Clinic,Mayo Clinic (Rochest...,Mayo Clinic Departme...,Drug:BCMA-directed CAR-T,proteasome inhibitor,CD38 antibody,Product:TMZ, Search all connections
Abstract Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data. Organization:Loyola University Me...,Maywood, IL,Drug:busulfan,Melphalan,bortezomib,Target:Proteasome, Search all connections
Abstract Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group. Organization:HealthTree Foundatio...,Janssen Scientific A...,Janssen Global Servi...,Drug:BCMA-targeted therap..., Search all connections
Abstract Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma. Clinical trial:22C.210,Organization:Sidney Kimmel Cancer...,Thomas Jefferson Uni...,Thomas Jefferson Uni...,Drug:daratumumab,hyaluronidase-fihj,Target:CD38,Congress:ASCO 2023, Search all connections
Abstract Identification of genes encoding targets associated with adverse events in multiple myeloma. Organization:Kansas State Univers...,Taussig Cancer Cente...,Cleveland Clinic Tau..., Search all connections
Abstract Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma. Organization:Mayo Clinic,Division of Hematolo...,Drug:axicabtagene ciloleu...,brexu-cel,Ide-cel,Target:BCMA×CD3, Search all connections
Abstract Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma. Clinical trial:IRB00097324,Organization:Emory University, At...,Department of Microb...,Emory Vaccine Center, Search all connections
Abstract Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM). Organization:Medical College of W...,Milwaukee,Froedtert & Medical ..., Search all connections
Abstract Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2. Clinical trial:LCAR-B38M,Organization:State Key Laboratory...,National Research Ce...,Shanghai Institute o..., Search all connections
Abstract CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Organization:Memorial Sloan Kette...,Sarah Cannon Researc...,UPMC Hillman Cancer ..., Search all connections
Abstract Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). Organization:Department of Blood ...,Drug:cilta-cel,fludarabine,cyclophosphamide, Search all connections
Abstract Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium. Organization:Simmons Comprehensiv...,UT Southwestern Medi...,Medical University o..., Search all connections
Abstract Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Clinical trial:CR108206,Organization:Amsterdam University...,Vrije Universiteit A...,Hematology Clinic, U..., Search all connections
Abstract Disparities in multiple myeloma: A global perspective on drug toxicity trends. Organization:DATA Consortium,Computational Compar...,Department of Mathem..., Search all connections
Abstract A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9. Clinical trial:209664,Organization:Memorial Sloan Kette...,Katedra i Klinika He...,Seoul National Unive..., Search all connections
Abstract Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. Clinical trial:CR108404,Organization:Clínica Universidad ...,CIMA,CIBERONC, Search all connections
Abstract Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database. Organization:University of Exeter...,Congress:ASCO 2024,ASCO 2020, Search all connections
Abstract Impact of multiple myeloma on outcomes of acute myocardial infarction: A propensity score matched analysis. Organization:College of Medical S...,Patan Academy of Hea...,Saint Clare's Health...,Congress:ASCO 2024, Search all connections
Abstract The impact of glucagon-like peptide-1 receptor agonists on proteasome inhibitor-associated cardiotoxicity in patients with multiple myeloma. Organization:Praxair Cancer Cente...,Congress:ASCO 2024, Search all connections
Abstract Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms. Organization:PVI,PeerView Institute f...,HealthTree Foundatio...,Congress:ASCO 2024, Search all connections
Abstract Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis. Drug:carfilzomib-dexameth...,dexamethasone,thalidomide, Search all connections
Abstract Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma. Drug:Aspirin,apixaban,Rivaroxaban,Target:COX-2,Factor Xa,COX-1,Organization:Cleveland Clinic Tau...,Congress:ASCO 2024, Search all connections
Abstract Impact of hyponatremia on multiple myeloma hospitalizations: A nationwide analysis. Organization:Brooklyn Hospital Ce...,Brooklyn ImmunoThera...,Nykode Therapeutics, Search all connections
Abstract Improving clinical outcomes in multiple myeloma: Weight maintenance strategies to reduce complications during autologous hematopoietic transplantation. Organization:Augusta University/U...,Georgia Cancer Cente...,Medical College of G...,Congress:ASCO 2024, Search all connections
Abstract Clinical outcomes and resource utilization in patients with multiple myeloma admitted with gastrointestinal bleeding. Organization:TriHealth Cancer Ins...,Trihealth - Cincinna...,Congress:ASCO 2024, Search all connections
Abstract The role of patient-driven education in decision-making for relapsed/refractory multiple myeloma. Organization:GlaxoSmithKline plc,Congress:ASCO 2024, Search all connections
Abstract Real-world comparison of adherence to branded 20 mg dexamethasone tablets and generic 4 mg dexamethasone tablets among patients with multiple myeloma. Organization:Edenbridge Pharmaceu...,Parsippany-Troy, NJ,Parsippany-Troy Hill...,Congress:ASCO 2024, Search all connections
Abstract Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis. Organization:Mayo Clinic,Phoenix Tissue Repai...,Azidus Brasil, Search all connections
Abstract Cost effective utilization of apheresis for stem cell transplantation in multiple myeloma. Organization:The Ohio State Unive...,Columbus, OH,The Ohio State Unive...,Congress:ASCO 2024, Search all connections
Abstract The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma. Organization:GlaxoSmithKline plc,Congress:ASCO 2024, Search all connections
Abstract Hospitalizations for multiple myeloma in the United States from 2011 to 2019: An analysis of trends and disparities. Organization:Steward Carney Hospi...,Congress:ASCO 2024,ASCO 2019, Search all connections
Abstract Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma. Organization:1DATA Consortium,Kansas State Univers...,Department of Hemato..., Search all connections
Abstract Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database. Drug:bortezomib,carfilzomib-dexameth...,ixazomib,Target:Proteasome,Organization:Rochester General Ho...,Dayanand Medical Col...,University of Arkans...,Congress:ASCO 2024, Search all connections
Abstract Exploring gender-based decision-making differences among patients with relapsed/refractory multiple myeloma. Organization:GlaxoSmithKline plc,Congress:ASCO 2024, Search all connections
Abstract Age-related differences in information-seeking behaviors of patients with multiple myeloma. Organization:HealthTree Foundatio...,The University of Te...,GlaxoSmithKline plc,Congress:ASCO 2024, Search all connections
Abstract Patient-reported treatment-related symptoms and use of the PRO-CTCAE for multiple myeloma clinical trials: A qualitative interview study. Drug:steroids,Target:steroids,Organization:Vector Psychometric ...,Janssen Global Servi...,Congress:ASCO 2024, Search all connections
Abstract Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database. Drug:pomalidomide-bortezo...,daratumumab,dexamethasone,Target:Cereblon,glucocorticoid recep...,CD38, Search all connections
Abstract Novel method for the detection of circulating tumor plasma cells in multiple myeloma. Organization:CytoGen Inc.,Congress:ASCO 2024, Search all connections
Abstract Incidence of thromboses and secondary cancers in patients with multiple myeloma after lenalidomide-based induction followed by maintenance as first-line therapy: A systematic review and meta-analysis. Drug:lenalidomide,Target:Cereblon (CRBN),Organization:UMKC School of Medic...,Congress:ASCO 2024, Search all connections
Abstract Incidence of infections in clinical trials of treatments for relapsed/refractory multiple myeloma: Systematic review and meta-analysis. Organization:Pennsylvania State U...,Congress:ASCO 2024, Search all connections
Abstract Talquetamab (Tal) therapy in relapsed/refractory (R/R) multiple myeloma (MM): Assessing weight loss and dysgeusia. Drug:talazoparib,Target:CD3,GPRC5D,Organization:University of Jordan,Congress:ASCO 2024, Search all connections
Abstract Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma. Drug:Belamaf,Target:B cell maturation an...,Organization:GlaxoSmithKline plc,GSK ONCOLOGY,Congress:ASCO 2024, Search all connections
Abstract Outcomes of ide-cel in patients with relapsed/refractory multiple myeloma: A single-institution experience. Drug:idecabtagene vicleuc...,Teclistamab,Product:talquetamab,Target:talquetamab,Teclistamab,B-Cell Maturation An...,Organization:University of Califo...,University of Califo..., Search all connections
Abstract Analyzing the impact of type 1 and type 2 diabetes on patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM): A retrospective study at a tertiary care center. Organization:SUNY Downstate Healt...,Congress:ASCO 2024, Search all connections
Abstract In-hospital outcomes of autologous stem cell transplantation in patients with multiple myeloma with versus without heart failure. Organization:Florida State Univer...,University of Miami ...,Florida Cancer Speci...,Congress:ASCO 2024, Search all connections
Abstract Survival shifts in multiple myeloma: Evaluating the impact of therapeutic advances and racial disparities after a decade of change. Organization:Greenville, NC,Congress:ASCO 2024, Search all connections
Abstract Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience. Organization:Hematology/Oncology ...,University of Califo...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of GPRC5D-based monotherapies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis. Organization:Nepal Army Institute...,Vassar Brothers Medi...,Congress:ASCO 2024, Search all connections
Abstract Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM). Drug:Tocilizumab,Teclistamab,Target:BCMA×CD3,IL-6 receptor,CD3,Organization:Hopital Bretonneau,Congress:ASCO 2024, Search all connections
Abstract Class comparison of BCMA-directed therapies in relapsed multiple myeloma. Drug:BCMA directed CAR T ...,antibody drug conjug...,T cell engagers (TCE...,Target:BCMA×CD3,Organization:Division of Hematolo...,Mayo Clinic,Rochester, MN, Search all connections
Abstract OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). Product:OriCAR-017,Target:GPRC5D,Organization:Zhejiang University ...,Department of Hemato...,Bone Marrow Transpla...,Congress:ASCO 2024, Search all connections
Abstract Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies. Organization:Kansas State Univers...,1DATA Consortium,Computational Compar...,Congress:ASCO 2024, Search all connections
Abstract Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). Drug:lenalidomide,elotuzumab-pomalidom...,dexamethasone,Target:SLAMF7,Cereblon,TNF-alpha, Search all connections
Abstract Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial. Organization:Istituto Scientifico...,Congress:ASCO 2024, Search all connections
Abstract Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis. Drug:VenDex,PomDex,Target:BCL2,Organization:Alexandra Hospital -...,Azienda Ospedaliero-...,Würzburg University ..., Search all connections
Abstract Chalazion associated with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database. Drug:bortezomib,carfilzomib-dexameth...,ixazomib,Target:Proteasome,Organization:Dayanand Medical Col...,Congress:ASCO 2024, Search all connections
Abstract Use of CAR T cell vs non-CAR T cell therapy in the treatment of patients (pts) with multiple myeloma (MM) in the Medicare population. Organization:Humbi AI,Congress:ASCO 2024, Search all connections
Abstract Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies. Drug:BCMA-directed T-cell...,Target:BCMA×CD3,Organization:Mayo Clinic Florida,Regeneron Pharmaceut...,RTI Health Solutions,Congress:ASCO 2024, Search all connections
Abstract The effect of distance reiki on patient reported quality of life, correlated with changes in immune repertoires among patients with multiple myeloma: A pilot study. Organization:Mayo Clinic,Division of Hematolo...,Alliance Statistics ...,Congress:ASCO 2024, Search all connections
Abstract Unveiling a low-hanging fruit: Single-center study on secondary immunodeficiency in newly diagnosed chronic lymphocytic leukemia and multiple myeloma. Organization:Rochester General Ho...,Congress:ASCO 2024, Search all connections
Abstract Assessment of health-related quality of life (HRQoL) in triple-class–exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial. Drug:linvoseltamab,Target:CD3,B-Cell Maturation An...,Organization:Indiana University S...,Louisville, KY,Clinical trial:R5458-ONC-1826,Congress:ASCO 2024, Search all connections
Abstract Improving the multiple myeloma and clinical trial awareness among Los Angeles County adults. Organization:Encino,Congress:ASCO 2024, Search all connections
Abstract Hospitalization risk in multiple myeloma episodes of care. Organization:McKesson,The US Oncology Netw...,The Woodlands,Congress:ASCO 2024, Search all connections
Abstract Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis. Organization:Genentech,Genesis Research,AbbVie Inc., North C...,Congress:ASCO 2024, Search all connections
Abstract Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32. Drug:Elranatamab,elotuzumab-pomalidom...,pomalidomide-bortezo...,Target:CD3,Pomalidomide,Dexamethasone, Search all connections
Abstract MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). Drug:Elranatamab,iberdomide,Target:BCMA×CD3,CD3,CELMoD,Organization:Pfizer Oncology Divi...,Clinical trial:C1071030,Congress:ASCO 2024, Search all connections
Abstract 1p and 1q: Partners in crime in multiple myeloma. Drug:del(1p),gain 1q,amplification 1q,Target:gain 1q,del(1p),amplification 1q,Organization:The Ohio State Unive...,The Ohio State Unive..., Search all connections
Abstract Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma. Drug:daratumumab,PI3K,IMiD,Target:CD38,IMiDs,PIK3CA,Organization:Myeloma Service,Department of Medici..., Search all connections
Abstract Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Drug:linvoseltamab,linvoseltamab,Target:B-cell maturation an...,CD3,B-Cell Maturation An...,Organization:Mayo Clinic,University Medical C...,Regeneron Pharmaceut..., Search all connections
Abstract Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. Organization:Myeloma Center,Congress:ASCO 2024, Search all connections
Abstract Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma. Drug:belantamab mafodotin,Elotuzumab,Target:BCMA×CD3,SLAMF7,Organization:Yale School of Publi...,Yale University Shoo...,Clinical trial:2000028918,Congress:ASCO 2024, Search all connections
Abstract Genome-wide 5-hydroxymethylation mapping and epigenetic pathways in multiple myeloma. Organization:Department of Preven...,British Columbia Can...,Department of Chemis...,Congress:ASCO 2024, Search all connections
Abstract Real-world outcomes (RWO) with tandem transplantation in patients (pts) with newly diagnosed multiple myeloma (NDMM). Organization:COTA, Inc.,Congress:ASCO 2024, Search all connections
Abstract Access to palliative care in patients with multiple myeloma in the USA: A National Cancer Database (NCDB) analysis of years 2004-2020. Organization:Cleveland Clinic Flo...,Congress:ASCO 2024,ASCO 2020, Search all connections
Abstract Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Drug:linvoseltamab,Teclistamab,Target:BCMA×CD3,CD3,Organization:Icahn School of Medi...,Department of Lympho...,The University of Te..., Search all connections
Abstract Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT). Organization:COTA, Inc.,Congress:ASCO 2024, Search all connections
Abstract First relapse in patients with multiple myeloma: Outcomes and predictors. Organization:Mayo Clinic,Rochester Regional H...,MN,Congress:ASCO 2024, Search all connections
Abstract Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant. Organization:Univ Hosps of Clevel...,Congress:ASCO 2024, Search all connections
Abstract From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity. Organization:Division of Public H...,Congress:ASCO 2024, Search all connections
Abstract Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM). Drug:belantamab mafodotin,BVd,DVd,Target:B-cell maturation an...,Organization:Clinica São Germano,...,Medical University o...,Samodzielny Publiczn..., Search all connections
Abstract Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment. Drug:apixaban,warfarin,immunomodulatory dru...,Target:Vitamin K epoxide re...,Factor Xa,Organization:Mount Auburn Hospita...,Unity Hospital,Rochester Regional H..., Search all connections
Abstract Uncontrolled diabetes mellitus and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans. Organization:Research Service,St Louis Veterans Af...,Congress:ASCO 2024, Search all connections
Abstract Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: Activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed/refractory multiple myeloma (RRMM). Drug:ARI0002h,proteasome inhibitor,immunomodulatory dru...,Target:BCMA×CD3,CD38,Proteasome,Organization:IMIB-Pascual Parrill..., Search all connections
Abstract Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy. Drug:bortezomib,dexamethasone,cyclophosphamide,Target:cyclophosphamide,Proteasome,CD38, Search all connections
Abstract Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19. Organization:Hackensack Universit...,John Theurer Cancer ...,Congress:ASCO 2024,ASCO 2022, Search all connections
Abstract OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Drug:Teclistamab,Tocilizumab,Target:IL-6 receptor,BCMA×CD3,CD3,Organization:Denver, CO,Colorado Blood Cance...,Eugene, OR, Search all connections
Abstract Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup. Drug:ciltacabtagene autol...,cilta-cel,lenalidomide,Target:Cereblon,BCMA×CD3,Organization:Myeloma Service, Dep...,Clinical trial:CR108581,Congress:ASCO 2024, Search all connections
Abstract Population attributable fractions for risk factors for the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in the Veteran population. Organization:Saint Louis Universi...,Division of Hematolo...,Saint Louis VA Medic...,Congress:ASCO 2024, Search all connections
Abstract Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM). Drug:mezigdomide,dexamethasone,Target:Cereblon,Dexamethasone,IKZF3,Organization:NIHR UCLH Clinical R...,Department of Clinic..., Search all connections
Abstract Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM). Drug:ABBV-383,dexamethasone,Target:BCMA×CD3,CD3,glucocorticoid recep...,Organization:Levine Cancer Instit...,Froedtert & Medical ...,Clinical trial:TNB383B.0001, Search all connections
Abstract Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire. Drug:belantamab mafodotin,lenalidomide,dexamethasone,Target:lenalidomide,BCMA×CD3,Glucocorticoid recep...,Organization:Health Data Speciali...,Clinical trial:EAE-2020/MM0107, Search all connections
Abstract Real world outcomes of high dose melphalan conditioning prior to autologous stem cell transplant in extramedullary multiple myeloma vs. multiple myeloma without extramedullary involvement: A single center experience. Organization:Los Angeles General ...,University of Southe...,University of Southe...,Congress:ASCO 2024, Search all connections
Abstract Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma. Drug:Elotuzumab,Pomalidomide,dexamethasone,Target:lenalidomide,Corticosteroid recep...,Pomalidomide, Search all connections
Abstract Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Drug:Teclistamab,Target:CD3,B-Cell Maturation An...,Organization:University College L...,Hematología Hospital...,Congress:ASCO 2024, Search all connections
Abstract Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Organization:Division of Hematolo...,Department of Intern...,Yale School of Medic...,Congress:ASCO 2024, Search all connections
Abstract Patterns and predictors of electronically measured oral anticancer medication (OAM) adherence among patients with multiple myeloma (MM). Organization:Eshelman School of P...,University of Pittsb...,University of Pittsb...,Congress:ASCO 2024, Search all connections
Abstract Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma. Drug:Teclistamab,Target:BCMA×CD3,CD3,Organization:Horsham, PA,Congress:ASCO 2024, Search all connections
Abstract Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy. Organization:Division of Nephrolo...,Congress:ASCO 2024, Search all connections
Abstract Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Drug:ABBV-383,Target:BCMA×CD3,CD3,Organization:Froedtert & Medical ...,Tulane Cancer Center...,Medizinische Klinik ...,Clinical trial:TNB383B.0001,Congress:ASCO 2024, Search all connections
Abstract Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis. Drug:daratumumab,cyclophosphamide,bortezomib,Target:Proteasome,cyclophosphamide,NF-κB, Search all connections
Abstract Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Drug:ABBV-383,ABBV-383,Target:BCMA×CD3,CD3,Organization:Froedtert & Medical ...,Tulane Cancer Center,Tulane University Sc..., Search all connections
Abstract Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3. Drug:ide-cel,Tocilizumab,Ide-cel,Target:IL-6 receptor,BCMA (B-cell maturat...,BCMA×CD3,Organization:Bristol Myers Squibb,Mayo Clinic, Search all connections
Abstract Second primary B-ALL after exposure to lenalidomide for multiple myeloma: A US multicenter study. Organization:Division of Hematolo...,The University of No...,Columbia University ..., Search all connections
Abstract Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9. Drug:Elranatamab,Target:BCMA×CD3,CD3,Organization:Japanese Red Cross M...,St. David's South Au...,Clinical trial:C1071009,Congress:ASCO 2024, Search all connections
Abstract Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy. Drug:Teclistamab,idecabtagene vicleuc...,ciltacabtagene autol...,Product:talquetamab,Target:idecabtagene vicleuc...,talquetamab,BCMA×CD3, Search all connections
Abstract Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies. Product:talquetamab,Drug:Tociluzumab,Target:IL-6 receptor,CD3,GPRC5D,Organization:University of South ...,H. Lee Moffitt Cance...,Moffitt Cancer Cente..., Search all connections
Abstract BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. Drug:Ide-cel,cilta-cel,pembrolizumab,Target:BCMA×CD3,PD-1,Organization:The University of Te...,H. Lee Moffitt Cance...,University of Pennsy..., Search all connections
Abstract Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma. Organization:Cleveland Clinic Ler...,Cleveland Clinic Tau...,Case Western Reserve...,Drug:corticosteroids,FDA-approved anti-my...,Target:FDA-approved anti-my...,corticosteroids,Congress:ASCO 2024, Search all connections
Abstract Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma. Organization:Johns Hopkins Sidney...,Johns Hopkins Univer...,Drug:Teclistamab,Tocilizumab,dexamethasone,Target:Dexamethasone,Interleukin-6 recept...,CD3, Search all connections
Abstract Association between financial fragility and treatment patterns in multiple myeloma. Organization:Fred Hutchinson Canc...,Seattle, WA,Congress:ASCO 2024, Search all connections
Abstract Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). Organization:Princess Margaret Ca...,Ankara University,University Hospital ..., Search all connections
Abstract Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Organization:University of Chicag...,Department of Medici...,University of Chicag...,Drug:lenalidomide,Target:Cereblon,Congress:ASCO 2024, Search all connections
Abstract Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Organization:Division of Hematolo...,Stanford University ...,University of Kansas..., Search all connections
Abstract All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. Organization:Centre Hospitalier U...,Centre Hospitalier U...,Vendée Departmental ..., Search all connections
Abstract Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM). Organization:Centre Hospitalier U...,Ankara University,University of Athens, Search all connections
Abstract Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. Organization:Saint-Louis Hospital,APHP,University Paris Cit..., Search all connections
Abstract Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. Organization:University of Alabam...,University Medical C...,Amsterdam University..., Search all connections
Abstract DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). Organization:Hospital Universitar...,Instituto de Investi...,Centro de Investigac..., Search all connections
Abstract Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Organization:Department of Hemato...,Hematology Departmen...,National and Kapodis..., Search all connections
Abstract Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Organization:Université de Poitie...,Hôpital Haut Leveque...,ECSTRA, Centre de Re..., Search all connections
Abstract Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Organization:University of Lille,CHU Lille - Hopital ...,Department of Clinic..., Search all connections
Abstract First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. Organization:University College L...,University Hospital ...,Medical College of W..., Search all connections
Abstract Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. Organization:Weill Cornell Medica...,Fox Chase Cancer Cen...,Arnie Charbonneau Ca..., Search all connections
Abstract A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3. Organization:Clinica São Germano,...,General Hospital Eva...,Department of Intern..., Search all connections
Abstract LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. Organization:Karmanos Cancer Inst...,Ziekenhuis Netwerk A...,Regeneron Pharmaceut...,Product:Linvoseltamab,Target:BCMA×CD3,CD3,Clinical trial:R5458-ONC-1826,Drug:linvoseltamab, Search all connections
Abstract Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Organization:Gracell Biotechnolog...,Product:GC012F,Target:B cell maturation an...,BCMA×CD3,CD19,Drug:GC012F,Congress:ASCO 2023,ASCO 2023, Search all connections
Abstract Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). Organization:University of Chicag...,Novartis Institutes ...,Medical College of W...,Product:PHE885,Target:B cell maturation an...,Clinical trial:CADPT07A12101, Search all connections
Abstract Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. Organization:Vanderbilt Universit...,University Hospital ...,Helen Diller Family ..., Search all connections
Abstract First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Organization:Sackler School of Me...,Hospital Universitar...,McGill University an..., Search all connections
Abstract Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. Organization:Schleswig-Holstein U...,Hospital Salzburg Pa...,University Hospital ..., Search all connections